Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4(+) T cells.
about
Detection and quantitation of eosinophils in the murine respiratory tract by flow cytometry.In Hot Pursuit of the First Vaccine Against Respiratory Syncytial VirusBiomarkers of respiratory syncytial virus (RSV) infection: specific neutrophil and cytokine levels provide increased accuracy in predicting disease severityRSV-specific anti-viral immunity is disrupted by chronic ethanol consumptionRespiratory syncytial virus synergizes with Th2 cytokines to induce optimal levels of TARC/CCL17.Pulmonary eosinophilia is attenuated by early responding CD8(+) memory T cells in a murine model of RSV vaccine-enhanced disease.Proliferative expansion and acquisition of effector activity by memory CD4+ T cells in the lungs following pulmonary virus infectionFas ligand is required for the development of respiratory syncytial virus vaccine-enhanced diseaseThe number of respiratory syncytial virus (RSV)-specific memory CD8 T cells in the lung is critical for their ability to inhibit RSV vaccine-enhanced pulmonary eosinophilia.Differential role of gamma interferon in inhibiting pulmonary eosinophilia and exacerbating systemic disease in fusion protein-immunized mice undergoing challenge infection with respiratory syncytial virusVbeta14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSVProtective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG.The increased type-1 and type-2 chemokine levels in children with acute RSV infection alter the development of adaptive immune responses.Immune responses and disease enhancement during respiratory syncytial virus infectionHeterologous immunity between virusesRespiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV.Heterologous immunity: immunopathology, autoimmunity and protection during viral infections.Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vectorIdentification of immunodominant epitopes derived from the respiratory syncytial virus fusion protein that are recognized by human CD4 T cells.Biological challenges and technological opportunities for respiratory syncytial virus vaccine development.Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteinsDifferential chemokine expression following respiratory virus infection reflects Th1- or Th2-biased immunopathology.The cysteine-rich region and secreted form of the attachment G glycoprotein of respiratory syncytial virus enhance the cytotoxic T-lymphocyte response despite lacking major histocompatibility complex class I-restricted epitopes.Virus-like nanoparticle and DNA vaccination confers protection against respiratory syncytial virus by modulating innate and adaptive immune cells.Human papillomavirus type 16 E7 peptide-directed CD8+ T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 proteinNanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease.Development of safe and effective RSV vaccine by modified CD4 epitope in G protein core fragment (Gcf).Pathogenic role for virus-specific CD4 T cells in mice with coronavirus-induced acute encephalitis.T cells are not required for pathogenesis in the Syrian hamster model of hantavirus pulmonary syndrome.Quantifying antigen-specific CD4 T cells during a viral infection: CD4 T cell responses are larger than we think.Specific history of heterologous virus infections determines anti-viral immunity and immunopathology in the lung.Baculovirus-based Vaccine Displaying Respiratory Syncytial Virus Glycoprotein Induces Protective Immunity against RSV Infection without Vaccine-Enhanced DiseaseNovel antigens for RSV vaccines.Universal vaccine against respiratory syncytial virus A and B subtypes.Age at first viral infection determines the pattern of T cell-mediated disease during reinfection in adulthoodRSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infection.Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance PSingle intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infectionPulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein.An alphavirus replicon-based human metapneumovirus vaccine is immunogenic and protective in mice and cotton rats.
P2860
Q24657793-075321C9-4529-48A9-B191-93AF181BF8F4Q26748856-514F3F56-06B4-4E65-8462-DB4C2348E88DQ27010165-EBE3115D-1F6B-4D60-9891-062DC9BA9D11Q28394949-D33E123F-BA23-47C3-A265-F5F46C3205B9Q30412460-4D88F605-92FD-4B39-9A7D-16065E87AF5FQ30435871-841EB0A1-96C3-40F7-A1EE-98D1733E5D9FQ30436432-A1EED7B2-6B3F-4290-9EB3-D3D3C3C16BA9Q30436942-0DDE4A8A-133D-4C25-8778-26A6950FFE35Q30437797-475695AF-0641-477A-97D2-2D94CC75EAE3Q30441455-FD1542DB-1FEC-478F-89A7-E42E61F49EC9Q30448968-24073035-0C70-485C-B793-DC959E9707B5Q30485791-4D0DDCF5-A78E-47AB-978B-3183FD3C605AQ33809843-34703D3C-1D8C-4918-A099-0502D71900B6Q33937152-C98A95FA-A81F-4519-B7AB-DEC2C0AB3D27Q34051846-25953AB4-F1B6-4C6B-99CF-84253F006D12Q34151000-4C451B4D-A8C4-44BF-B309-46436C070269Q34159981-568AEB09-655D-4DB7-8447-004848A98046Q34302198-4033B38E-9D4D-4BF5-BDA5-E987B2E86EE4Q34465367-8CB9E40C-F036-438D-A649-79D5B72AC60AQ34504791-CEBF6C1B-8291-42C5-99AB-BA0947F1F8C2Q34616642-B8A3E90C-7471-4D05-B0E8-781AB4ECCB24Q34647519-5EA78ED8-C6FA-4FFD-A3A2-D2D08125514BQ34651258-297E4593-FA28-4240-AE8F-6EC428ED60A6Q34791209-806B79A1-4E76-441E-B6CB-533BD78597DDQ34975376-BE637AA9-A424-4CBC-927E-66BA00875CCDQ34990420-DAFF994F-BD03-4629-96E6-5C2E8567A608Q35149594-94EE3D07-87A6-408A-8A91-BD7ADD91478BQ35221875-10C48EB4-03B7-44DA-8DBC-1BC3323C6DFCQ35383088-7F3AD8D1-6E49-4DF1-824E-1B053EC1F139Q35566829-F8EC84B8-07EC-44E8-AF10-21EF0035A4C6Q35792192-B55C8DAB-2982-4335-B6F9-CC96F9A2D663Q35897609-D2491FED-CE7B-4855-881E-CA3845BF4A9FQ36005960-AE9B278D-42D6-4FCA-97FC-69E3CF7E5E41Q36338294-DDC6223F-9C8B-438D-A542-496D6DDE76FBQ36371040-CDD1D483-425B-496A-89F7-79B9E187FB5AQ36438145-E7EC2771-CAF8-49FA-BBAC-75BA145317A8Q36464353-E5C61261-CE31-4475-84D2-C7C3C88D9DAFQ36483809-A4401256-87F8-4704-AF91-083C56EC308EQ36838539-BBAD906D-A089-4215-8847-8C6946D469EFQ36949797-5321BBE3-85DC-43FF-BDC1-730289987E2C
P2860
Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4(+) T cells.
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Immunopathology in RSV infecti ...... tigen-specific CD4(+) T cells.
@ast
Immunopathology in RSV infecti ...... tigen-specific CD4(+) T cells.
@en
type
label
Immunopathology in RSV infecti ...... tigen-specific CD4(+) T cells.
@ast
Immunopathology in RSV infecti ...... tigen-specific CD4(+) T cells.
@en
prefLabel
Immunopathology in RSV infecti ...... tigen-specific CD4(+) T cells.
@ast
Immunopathology in RSV infecti ...... tigen-specific CD4(+) T cells.
@en
P2093
P1433
P1476
Immunopathology in RSV infecti ...... ntigen-specific CD4(+) T cells
@en
P2093
P304
P356
10.1016/S1074-7613(01)00209-6
P407
P577
2001-10-01T00:00:00Z